Inbrija Generic Name & Formulations
Legal Class
Rx
General Description
Levodopa 42mg; per cap; dry pwd for oral inh.
Pharmacological Class
Dopamine precursor.
How Supplied
Caps (w. inhaler)—60, 92
Manufacturer
Generic Availability
NO
Inbrija Indications
Indications
Intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.
Inbrija Dosage and Administration
Adult
For oral inh only; use with Inbrija inhaler. Do not swallow caps. Inhale contents of 2 caps (84mg) as needed, up to 5 times daily. Max dose per OFF period: 84mg; max daily dose: 420mg.
Children
Not established.
Inbrija Contraindications
Contraindications
During or within 14 days of nonselective MAOIs (eg, phenelzine, tranylcypromine).
Inbrija Boxed Warnings
Not Applicable
Inbrija Warnings/Precautions
Warnings/Precautions
Sleep disorders: consider discontinuing if significant daytime sleepiness occurs.
Withdrawal-emergent hyperpyrexia or confusion: avoid rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. Increased risk of hallucinations and psychosis. Major psychotic disorder, asthma, COPD, chronic lung disease: not recommended. Impulse control disorders: consider discontinuing if occurs. Glaucoma: monitor IOP. Pregnancy. Nursing mothers.
Inbrija Pharmacokinetics
See Literature
Inbrija Interactions
Interactions
See Contraindications. Orthostatic hypotension with MAO-B inhibitors; monitor. Antagonized by dopamine D2 receptor antagonists (eg, phenothiazines, butyrophenones, risperidone, metoclopramide), isoniazid, iron salts; monitor. May cause false (+) plasma/urine results suggesting pheochromocytoma.
Inbrija Adverse Reactions
Adverse Reactions
Cough, nausea, upper respiratory tract infection, sputum discolored; dyskinesia (adjust doses), CNS disturbances (eg, hallucinations, confusion, somnolence), bronchospasm, increased IOP, lab abnormalities.
Inbrija Clinical Trials
See Literature
Inbrija Note
Not Applicable
Inbrija Patient Counseling
See Literature
Images
